SHMD (CEO Song Min-young), an artificial intelligence (AI)-based blood flow diagnostic solution company, announced on the 20th that it was selected as the final winner at 'Health-tech Demoday' held in Los Angeles, USA.
The event was hosted by LAVA (Los Angeles Venture Association), an American venture capital association, and SHMD received the award in recognition of the technological perfection and innovation of its wearable ultrasound device, CEREBAND.
Cereband is a non-invasive, head-worn device that utilizes AI algorithms to analyze cerebral blood flow data in real time and detects the early risk of blood clots, which can be considered a precursor to stroke. The judges praised its potential for stroke prevention.
SHMD is a company that has internalized three core competencies: medical device development, AI algorithm design, and global licensing strategy. It has been evaluated that its strategy of integrating research and development (R&D) and regulatory response has led to rapid product commercialization.
Additionally, remote monitoring and hospital electronic medical record (EMR/EHR) integration features have garnered attention as solutions that meet the demand for addressing healthcare accessibility gaps and reducing healthcare costs in the United States.
SHMD is currently advancing its AI algorithms through clinical collaborations with domestic and international medical institutions and is preparing for certification from the U.S. Food and Drug Administration (FDA) and Europe's CE.
CEO Song Min-young said, “This award is a recognition of our technological competitiveness in the global market,” and added, “We will contribute to shifting the paradigm of stroke diagnosis from treatment to prevention, and expand our presence in the global market, including the United States.”
- See more related articles
You must be logged in to post a comment.